On November 3, to enhance investors' understanding of publicly listed companies, the "Investors Enter Eyebright Medical—Shareholders' Day" event was successfully held under the guidance of the Beijing Securities Regulatory Bureau. Organized by the Beijing Listed Companies Association and supported by CITIC Securities, CITIC Jinpeng Securities, and CICC, the event was hosted by Eyebright Medical.

Investors from public and private funds, securities analysts, individual investor representatives, and authoritative media from the capital markets participated in this event. Through on-site visits and in-depth discussions, they collectively witnessed Eyebright Medical's high-quality innovative achievements and developmental progress.

Group Picture from the Event

Leaders from the Beijing Securities Regulatory Bureau indicated in their speeches that this event has created an effective and in-depth communication platform for investors and the company. This serves as a practical step in promoting the standardized operation of publicly listed companies, protecting investors' rights, and facilitating the high-quality development of the capital market.

Li Honghai, Secretary-General of the Beijing Listed Companies Association, emphasized in his address that the association is dedicated to building a communication bridge between investors and publicly listed companies. Eyebright Medical, as a representative of outstanding enterprises thriving in the fertile ground of the capital city, showcases frontier innovative capabilities in the ophthalmic field. This event aims to help investors gain a deeper and more intuitive understanding of such high-quality companies, further promoting the high-quality development of the capital market in the region.

Dr. Xie Jiangbing, Founder, Chairman, and General Manager of Eyebright Medical, warmly welcomed the guests in attendance. He highlighted that the rapid development of Eyebright Medical heavily relies on the long-term trust and support of its investors. Moving forward, the company will adhere to a long-term development philosophy, focusing on high-quality innovation as its core driving force, and continuously enhancing its core competitiveness to create sustainable long-term value for investors.

Dr. Xie Jiangbing, Founder, Chairman, and General Manager of Eyebright Medical

As a leading enterprise in China's ophthalmic field, Eyebright Medical has launched several domestically innovative and internationally advanced products since its establishment, continually attracting attention in the capital market due to its solid innovation capabilities.

Dr. Wang Zhao, the company's Director, Deputy General Manger, and Chief R&D Officer, systematically showcased the company’s innovative achievements during this event. In terms of product innovation, leveraging its core technology platform, the company plans to launch several flagship products in 2025. Among these are the Loong Crystal™ PR Phakic Intraocular Lens for myopia correction in adults, which has received significant attention from investors, and the Proming lens designed for vision correction in aphakic patients following cataract surgery.

In the realm of material innovation, the company’s independently developed high-oxygen-permeable silicone hydrogel material has reached the technical level of leading international brands and has successfully obtained its registration certificate. Additionally, the company is extending core optical technologies such as EDF into the field of functional optometric products, continually expanding its boundaries of innovation.

Dr. Wang Zhao, Director, Vice President, and Chief R&D Officer of Eyebright Medical

The Loong Crystal™ PR Phakic Intraocular Lens is the first aspheric intraocular lens in the country, and it is expected to break the long-standing monopoly of international manufacturers. During the event, attendees had the opportunity to explore Eyebright Medical’s research and production frontlines, witnessing the entire process of the Loong Crystal™ PR from research and development to production.

In the interactive experience session, guests not only tried on the newly certified high-oxygen-permeable silicone hydrogel contact lenses but also observed the innovative application of Eyebright Medical’s iBright AI Digital Fitting System for myopia control, explained by R&D engineers. This system marks a revolutionary shift from "experience-driven" to "AI-driven" fittings, completing a fully parameterized custom solution in just 20 seconds and assisting in achieving clinical breakthroughs with "one fitting, one success" at the nanoscale precision level.

Introduction to Eyebright Medical's iBright AI Digital Fitting System

From strategy to the frontline, and from core products to intelligent services, this immersive experience provided investors with a comprehensive understanding of Eyebright Medical's technological strength and innovative framework leading the industry transformation.

To offer investors diverse industry insights and inform their investment decisions, the event featured a roundtable discussion. Four industry analysts with deep expertise in the medical field engaged in an in-depth exploration of the current opportunities and challenges facing the medical device sector. The analysts pointed out that current centralized procurement policies have shifted from a sole focus on low prices to fostering innovation, providing a more favorable development environment for truly clinically valuable innovative products.

In this context, domestic medical device companies are entering a new development phase characterized by core innovation, domestic substitution, and overseas expansion as breakthroughs. During the discussion, they used Eyebright Medical as an example to analyze the key factors for establishing long-term competitiveness in medical device companies. They noted that the company continues to increase its innovation investment in core areas such as materials and technology, benchmarking against international ophthalmic giants, and significantly leading the industry in its layout within the contact lens market. This underscores its strategic capability to position itself according to long-term trends.

Moreover, Eyebright Medical's "R&D-Production-Sales" closed-loop system effectively promotes the commercialization of core R&D achievements, continually solidifying and enhancing the company's competitive barriers.

Roundtable Discussion Session

During the final Q&A session with executives, the management team of Eyebright Medical engaged in in-depth communication with investors regarding the company's strategy, business progress, and industry trends, further enhancing investors' understanding of the company's development path and value concepts.

The Executive Q&A Session at Eyebright Medical

This investor engagement event showcased Eyebright Medical's development vision, driven by innovation and guided by long-termism, through various formats, including on-site visits, roundtable discussions, and interactions with executives. In the future, Eyebright Medical will continue to maintain a transparent and diverse investor communication mechanism, actively conveying the company's value through systematic and standardized investor relations management.